Logo image of TLMD

SOC TELEMED INC (TLMD) Stock Fundamental Analysis

NASDAQ:TLMD - Nasdaq - Common Stock

3  0 (0%)

After market: 3 0 (0%)

Fundamental Rating

1

Overall TLMD gets a fundamental rating of 1 out of 10. We evaluated TLMD against 108 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of TLMD have multiple concerns. TLMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TLMD has reported negative net income.
TLMD Yearly Net Income VS EBIT VS OCF VS FCFTLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 0 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -31.66%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLMD Yearly ROA, ROE, ROICTLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 0 -20 -40 -60 -80

1.3 Margins

Industry RankSector Rank
OM -57.36%
PM (TTM) -69.61%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLMD Yearly Profit, Operating, Gross MarginsTLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 0 20 -20 -40 -60 -80

More info and screens

3

2. Health

2.1 Basic Checks

TLMD has more shares outstanding than it did 1 year ago.
There is no outstanding debt for TLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TLMD Yearly Shares OutstandingTLMD Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 20M 40M 60M
TLMD Yearly Total Debt VS Total AssetsTLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 50M 100M 150M 200M 250M

2.2 Solvency

TLMD has an Altman-Z score of 0.35. This is a bad value and indicates that TLMD is not financially healthy and even has some risk of bankruptcy.
TLMD has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACCN/A
WACCN/A
TLMD Yearly LT Debt VS Equity VS FCFTLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 3.33 indicates that TLMD has no problem at all paying its short term obligations.
A Quick Ratio of 3.25 indicates that TLMD has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 3.25
TLMD Yearly Current Assets VS Current LiabilitesTLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for TLMD have decreased strongly by -192688.57% in the last year.
EPS 1Y (TTM)-192688.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TLMD will show a decrease in Earnings Per Share. The EPS will decrease by -6.44% on average per year.
The Revenue is expected to grow by 28.52% on average over the next years. This is a very strong growth
EPS Next Y-42.09%
EPS Next 2Y-11.37%
EPS Next 3Y-5.16%
EPS Next 5Y-6.44%
Revenue Next Year61.44%
Revenue Next 2Y43.62%
Revenue Next 3Y33.9%
Revenue Next 5Y28.53%

3.3 Evolution

TLMD Yearly Revenue VS EstimatesTLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
TLMD Yearly EPS VS EstimatesTLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLMD. In the last year negative earnings were reported.
Also next year TLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLMD Price Earnings VS Forward Price EarningsTLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLMD Per share dataTLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

TLMD's earnings are expected to decrease with -5.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.37%
EPS Next 3Y-5.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOC TELEMED INC

NASDAQ:TLMD (4/5/2022, 8:00:02 PM)

After market: 3 0 (0%)

3

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-31 2022-03-31
Earnings (Next)05-11 2022-05-11
Inst Owners0.1%
Inst Owner Change0%
Ins Owners7.43%
Ins Owner Change0%
Market Cap303.99M
Analysts75
Price Target3.06 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.44
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.45
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.23
BVpS1.76
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -57.36%
PM (TTM) -69.61%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 3.25
Altman-Z 0.35
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-192688.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.51%
EPS Next Y-42.09%
EPS Next 2Y-11.37%
EPS Next 3Y-5.16%
EPS Next 5Y-6.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year61.44%
Revenue Next 2Y43.62%
Revenue Next 3Y33.9%
Revenue Next 5Y28.53%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A